Inhibition of phospholipase C, phospholipase A2, phosphodiesterase
Brite
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
13 Agents affecting sensory organs
131 Ophthalmic agents
1319 Others
D01088 Pemirolast potassium (JP18/USAN)
4 Agents affecting cellular function
44 Allergic agents
449 Miscellaneous
4490 Miscellaneous
D01088 Pemirolast potassium (JP18/USAN)
Classification of Japanese OTC drugs [BR:br08313]
Agents for ophthalmologic use
64 Allergy eye drops
D01088 Pemirolast potassium (JP18/USAN)
Agents for otolaryngologic use
69 Oral medicine for nasal inflammation
D01088 Pemirolast potassium (JP18/USAN)
Risk category of Japanese OTC drugs [BR:br08312]
Second-class OTC drugs
Inorganic and organic chemicals
Pemirolast potassium
D01088 Pemirolast potassium (JP18/USAN)
Drug groups [BR:br08330]
Anti-allergic agent
DG01805 Mediator release inhibitor
DG02929 Pemirolast
D01088 Pemirolast potassium
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D01088 Pemirolast potassium
D01088 Pemirolast potassium tablets
D01088 Pemirolast potassium for syrup
D01088 Pemirolast potassium ophthalmic solution
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D01088
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D01088
Rx-to-OTC switch list in Japan [br08314.html]
D01088
Drug groups [BR:br08330]
Anti-allergic agent
DG01805 Mediator release inhibitor
DG02929 Pemirolast